CME Activities

Coming soon...

ONLINE PROGRAMS

Mar
16
Tue
Psoriatic Arthritis Grand Rounds Smart Reach Simulcast Replay
Mar 16 2021 @ 9:15 am Mar 16 2022 @ 10:15 am

Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic

 

PROGRAM CHAIR

Daniel Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles
University of Washington, Seattle, WA
University of Florence, Florence, Italy

 

SPEAKER FACULTY

Jon T. Giles, MD, MPH
Associate Professor of Medicine
Columbia University, Vagelos School of Physicians & Surgeons
New York, NY

 

PROGRAM OVERVIEW

This activity will cover the treatment and management of patients with psoriatic arthritis during the COVID-19 pandemic.

TARGET AUDIENCE

This activity is intended for rheumatologists and rheumatology advanced practice providers (NPs and PAs) who are involved in the care and treatment of patients with psoriatic arthritis.

LEARNING OBJECTIVES

On completing the program, attendees should be able to:

  • Identify the risk of COVID-19-related infections in PsA, along with their impact on therapeutic choice
  • Pursue strategies to optimize PsA therapy in the COVID-19 era while minimizing risks and adverse events
  • Assess methods for better evaluating and communicating with patients through telemedicine and virtual platforms
  • Apply new ways to initiate and manage PsA treatment, monitor PsA disease progression and address adverse events via virtual communication

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved and/or interested in the therapeutic management of patients with psoriatic arthritis.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosure
Daniel Furst, MD Dr. Furst reports that he is on the speakers bureau for CME. He also serves as a consultant for Actelion, Amgen, BMS, Corbus, Galapagos Novartis, and Pfizer. He has also provided grant/research support for Actelion, Amgen, BMS Corbus, Galapagos GSK, NIH, Novartis, Pfizer, Sanofi, and Roche/Genentech.
Jon T. Giles, MD, MPH Dr. Giles reports that he serves as a consultant for Gilead, Eli Lilly, Bristol Myers Squibb, AbbVie, and UCB; and discloses a relationship with Pfizer.

 

CME Content Review

The content of this activity was independently peer-reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was independently peer-reviewed.

The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
  • Diana Tommasi, PharmD, Medical Director for Med Learning Group has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures
  2. Participate in the enduring activity
  3. Complete post-test and evaluation form online.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only.  Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Mar
18
Thu
The RELIEF Initiative Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic
Mar 18 2021 @ 9:15 am Mar 18 2022 @ 10:15 am

The RELIEF Initiative
Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic

FACULTY


Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles, CA
University of Washington, Seattle, WA
University of Florence, Florence, Italy

Silvia Bellando-Randone, MD
Research Assistant, Department of Experimental and Clinical Medicine
Rheumatology Department of Geriatric Medicine, Division of Rheumatology and Scleroderma Unit
University of Florence, Florence, Italy

PROGRAM OVERVIEW

This situation room activity allows learners to practice making clinical decisions in the management of patients with psoriatic arthritis. Learners will view a simulated interaction between a patient and their physician and use information from the patient’s electronic chart to decide the next best course of action. Topics covered in this activity include assessment of disease severity, treatment selection, and managing patients with SARS-CoV-2 infection or exposure.


TARGET AUDIENCE

This activity is intended for rheumatologists and rheumatology advanced practice providers (NPs and PAs) who are involved in the care and treatment of patients with psoriatic arthritis.


LEARNING OBJECTIVES

  • Identify the risk of COVID-19-related infections in PsA, along with their impact on therapeutic choice
  • Pursue strategies to optimize PsA therapy in the COVID-19 era while minimizing risks and adverse events
  • Assess methods for better evaluating and communicating with patients through telemedicine and virtual platforms
  • Apply new ways to initiate and manage PsA treatment, monitor PsA disease progression and address adverse events via virtual communication

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with psoriatic arthritis.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Daniel E. Furst, MD is on the speakers’ bureau for CME. He also serves as a consultant for Actelion, Amgen, BMS, Corbus, Galapagos Novartis, and Pfizer. He has also provided grant/research support for Actelion, Amgen, BMS Corbus, Galapagos GSK, NIH, Novartis, Pfizer, Sanofi, and Roche/Genentech.

Silvia Bellando-Randone, MD has nothing to disclose.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Diana Tommasi, Medical Director of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CE credit for this online activity. To receive CME/CE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: March 18, 2021

EXPIRATION DATE: March 18, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

CLICK ON STATES TO SEE GRAND ROUNDS ACTIVITIES

Scroll to Top

Updates in the Treatment and Prevention of COVID-19

An investigational, oral COVID-19 antiviral candidate reduced the risk of hospitalization or death by 89% in an interim analysis

An investigational oral antiviral candidate consisting of PF-07321332 plus ritonavir (Paxlovid™) significantly reduced hospitalization and death in non-hospitalized adult patients with COVID-19 at high risk of progressing to severe illness. An interim analysis of the phase 2/3 EPIC-HR trial showed an 89% reduction in the risk of COVID-19-associated hospitalization or death from any cause at day 28 in the antiviral group compared with the placebo group in patients treated within three days of symptom onset (0.8% vs 7.0%, respectively; P <.0001). Similar results were observed in patients treated within five days of symptom onset (1.0% vs 6.7%; P <.0001). No deaths were reported in patients who received  the antiviral treatment compared with 10 deaths (1.6%) in patients who received placebo. Treatment-emergent adverse events were comparable between antiviral treatment (19%) and placebo (21%) groups and were mostly mild in intensity. Fewer serious adverse events (1.7% vs 6.6%) and discontinuation of the study drug due to adverse events (2.1% vs 4.1%) were observed in patients receiving the antiviral treatment compared with placebo, respectively.

Reference

Mahase E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713. Available at https://www.bmj.com/content/375/bmj.n2713